Egan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm Board
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today commented on an opinion issued by Egan-Jones Proxy Services (“Egan-Jones”) in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals...
Login to comment.